Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294772 | 0.87 | P2RX3 (0.36) | P2RX3TRPC5 | |
| SCHEMBL8294773 | 0.84 | IDH1 (0.36) | P2RX3TRPC5CA2 | |
| SCHEMBL8293133 | 0.83 | P2RX3 (0.35) | P2RX3TRPC5 | |
| SCHEMBL12852013 | 0.82 | TRPC5 (0.43) | P2RX3TRPC5 | |
| SCHEMBL4278120 | 0.81 | P2RX3 (0.33) | P2RX3TRPC5CA2 | |
| SCHEMBL8294800 | 0.80 | TRPC5 (0.38) | TRPC5 | |
| SCHEMBL8249749 | 0.76 | KDM4E (0.39) | — | |
| SCHEMBL6368794 | 0.75 | TRPC5 (0.43) | TRPC5 | |
| SCHEMBL8294757 | 0.75 | KCNH2 (0.39) | — | |
| SCHEMBL8285827 | 0.75 | MCHR1 (0.35) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| EP-1697347-B1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-02-23 | — | — | EP | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| WO-2005058874-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 | P2RX3 1849/4885TRPC5 2236/4885CA2 1278/4885 |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 | P2RX3 1861/4885TRPC5 2420/4885CA2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.